Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2022-10-25 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Zwołanie Nadzwyczajnego Walnego Zgromadzenia spółki Pharmena S.A. - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and announces the convening ('zwołaniu') of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia') of PHARMENA S.A. for November 22, 2022. It explicitly states that the management is enclosing ('w załączeniu przekazuje') the announcement along with the draft resolutions ('projektem uchwały'). Since this document is an announcement about scheduling a shareholder meeting and providing related materials (like draft resolutions), it strongly aligns with the purpose of an Annual General Meeting (AGM) related filing, even though it is an 'Extraordinary' meeting. The closest specific category is AGM-R (AGM Information), which covers presentations and materials shared during the AGM, which includes the notice and associated documents.
2022-10-25 Polish
Planowane wydzielenie działalności dermokosmetycznej - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document text, written in Polish, discusses the Management Board's plan to spin off (wydzielić) the dermo-cosmetic business as an organized part of the enterprise (ZCP). This action requires a resolution from the general meeting of shareholders (walne zgromadzenie akcjonariuszy), which the Board plans to convene on November 22, 2022, specifically to vote on this resolution. The core subject is a significant corporate restructuring/transaction (spin-off) that necessitates shareholder approval. This type of major corporate action, especially one involving the transfer of a significant business segment, falls under the scope of major corporate transactions or capital structure changes. Since the text explicitly mentions convening a general meeting to vote on a resolution regarding this major structural change, it strongly relates to corporate governance and major transactions. However, the most fitting category among the provided options for a major structural change/transaction that might require shareholder vote and is not explicitly a merger (TAR) or a simple share issue (SHA/POS) is often related to financing or capital structure changes, or sometimes treated as a significant regulatory event. Given the context of spinning off a business unit, which is a form of corporate reorganization, and the announcement of convening a shareholder meeting for a vote, it touches upon AGM/Voting (AGM-R/DVA). Since the primary focus is the *plan* for the spin-off and the subsequent call for the EGM/AGM to approve it, it is a significant corporate event announcement. If this were a formal notice of the meeting itself, it might lean towards AGM-R or PSI. Since it announces a major structural change that *triggers* the need for a shareholder vote, and it is not a standard financial report, it is best classified as a significant corporate action announcement. Given the options, 'Capital/Financing Update' (CAP) often covers major structural changes affecting the capital base or operational structure, or 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard announcements. Given the nature of the spin-off, which fundamentally alters the structure, 'CAP' is a plausible fit, but 'RNS' is safer for significant, non-standard corporate restructuring announcements that don't fit perfectly elsewhere. Let's re-evaluate: The text announces a major structural change (spin-off) and the calling of a shareholder meeting to approve it. This is a significant corporate event. Since there is no specific 'Spin-off Announcement' code, and it's not a standard financial report, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for a material, non-standard corporate action disclosure. The document length is short (1265 chars), suggesting it is an announcement rather than the full legal documentation of the spin-off itself.
2022-10-25 Polish
Raport z przeglądu MSSF skrócone SSF Pharmena-sig
Audit Report / Information Classification · 99% confidence The document is explicitly titled 'Sprawozdanie biegłego rewidenta' (Auditor's Report) and 'Raport niezależnego biegłego rewidenta z przeglądu śródrocznego skróconego skonsolidowanego sprawozdania finansowego' (Report of the independent auditor on the review of the interim condensed consolidated financial statements). It covers the period from January 1, 2022, to June 30, 2022, which is a six-month period, indicating an interim report. The content is the formal opinion/conclusion from the auditor based on a review (przegląd) according to ISA 2410, which is characteristic of an Audit Report or an Interim Report containing audit/review assurance. Since it is a formal report detailing the results of an audit/review on interim financial statements, the most appropriate classification is 'Audit Report / Information' (AR), as it is a standalone audit/review document, not the full Annual Report (10-K) or the comprehensive Interim Report (IR) itself, but the assurance component thereof. Given the explicit focus on the auditor's review conclusion, AR is the best fit. H1 2022
2022-08-26 Polish
Raport z przeglądu MSSF skrócone JSF Pharmena-sig
Audit Report / Information Classification · 99% confidence The document is titled "Sprawozdanie biegłego rewidenta" (Independent Auditor's Report) and specifically details a "Raport niezależnego biegłego rewidenta z przeglądu śródrocznego skróconego jednostkowego sprawozdania finansowego" (Independent Auditor's Report on the review of the condensed half-yearly separate financial statements) for the period ending June 30, 2022. This document contains the auditor's conclusion based on a review of interim financial statements. This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a general Interim Report (IR) which would contain the statements themselves, not just the auditor's review conclusion. The document length (4130 chars) is substantial enough to be the report itself, not just an announcement (RPA/RNS). H1 2022
2022-08-26 Polish
GK_PHR_Raport_za_I_polrocze_za_2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'SKONSOLIDOWANY RAPORT PÓŁROCZNY' (Consolidated Semi-Annual Report) for the period ending June 30, 2022. It contains detailed financial statements, including the consolidated statement of financial position, cash flows, and comprehensive income, as well as extensive notes and management disclosures. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2022
2022-08-26 Polish
220826_PHR_oswiadczenie zarządu_wybór audytora_1H2022
Audit Report / Information Classification · 95% confidence The document is titled "OŚWIADCZENIE ZARZĄDU W SPRAWIE PODMIOTU UPRAWNIONEGO DO BADANIA SPRAWOZDAŃ FINANSOWYCH" (Management Statement Regarding the Entity Authorized to Audit Financial Statements). The text explicitly states that the Management Board confirms the selection of the auditing firm for the semi-annual condensed individual and consolidated financial statements for the first half of 2022, confirming compliance with independence and professional standards. This content directly relates to the audit process and the auditor's qualifications, fitting the definition of an Audit Report / Information (AR), which covers applied accounting principles and results of internal/regulatory stress tests, or in this case, the formal declaration regarding the auditor selection process preceding the audit report itself. Given the options, AR is the closest fit as it deals with the audit function, although it is a declaration about the auditor rather than the final audit opinion. H1 2022
2022-08-26 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.